Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
126,748 studies indexed
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06929624 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | active not recruiting | Phase 3 | 282 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06936527 | XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation(XS-03-II201) | enrolling by invitation | Phase 1 / Phase 2 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
| 1 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT06952660 | Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | recruiting | Phase 4 | 100 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06963281 | Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | recruiting | Phase 1 | 285 | Fortvita Biologics (USA)Inc.INDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | recruiting | Phase 3 | 2,400 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | recruiting | Phase 2 | 250 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | recruiting | Phase 2 / Phase 3 | 982 | PfizerINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT07007559 | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer(ASPEN-09-03) | recruiting | Phase 2 | 120 | ALX Oncology Inc.INDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT07024680 | Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC(PRCC) | completed | — | 48 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)(DeLLphi-311) | recruiting | Phase 1 | 380 | AmgenINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07054190 | A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | recruiting | Phase 2 | 120 | Hoffmann-La RocheINDUSTRY | 7 | Sep 25, 2026 | clinicaltrials |
| NCT07060014 | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers | recruiting | Phase 1 | 22 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07066189 | Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC | recruiting | N/A | 160 | Yale UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07082920 | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | recruiting | Phase 1 | 140 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07088991 | Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia(NEREUS) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07089914 | Health Surveillance at University of Applied Science Hamburg (HAW)(HAW_HS2025) | completed | — | 679 | Jacobs University Bremen gGmbHOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07093567 | Opiophobia in Adults With Advanced Cancer | active not recruiting | — | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07104032 | IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)(IGNITE) | recruiting | Phase 3 | 132 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 7 | Sep 25, 2026 | clinicaltrials |
| NCT07105033 | Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer | recruiting | N/A | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07105046 | Facilitators and Barriers to Cancer Treatment Among Texas Residents | not yet recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07121322 | Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.(DACT-GCT) | recruiting | Phase 2 | 33 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07126548 | A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men | recruiting | N/A | 200 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07138274 | Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS | recruiting | Phase 2 | 90 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07142005 | Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer | recruiting | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07149220 | Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions.(FMS) | completed | Phase 1 | 7 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07149857 | A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel(CARTITUDE-10) | recruiting | Phase 2 | 60 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07150208 | T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis(THUMB) | recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07154290 | A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 300 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07164443 | A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)(KLK2-comPAS) | recruiting | Phase 3 | 1,203 | Janssen Research & Development, LLCINDUSTRY | 17 | Sep 25, 2026 | clinicaltrials |
| NCT07172243 | BE.Amycon Biobank & Data Registry UZ Leuven | recruiting | — | 505 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07179809 | Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer | recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07181161 | Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer(SEACLIFF) | recruiting | Phase 1 / Phase 2 | 283 | AstraZenecaINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT07183189 | A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 582 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07193550 | A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) | recruiting | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07194044 | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes(METTSEO) | recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07195591 | Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care(BRIDGES) | recruiting | Phase 3 | 766 | GT Medical Technologies, Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation(REVEAL-ND NPM1) | recruiting | Phase 3 | 468 | Syndax PharmaceuticalsINDUSTRY | 23 | Sep 25, 2026 | clinicaltrials |
| NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | recruiting | Phase 3 | 1,023 | Merck Sharp & Dohme LLCINDUSTRY | 28 | Sep 25, 2026 | clinicaltrials |
| NCT07217587 | Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis(EPIC) | recruiting | Phase 3 | 115 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07218926 | A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | recruiting | Phase 3 | 450 | GlaxoSmithKlineINDUSTRY | 19 | Sep 25, 2026 | clinicaltrials |
| NCT07219212 | A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma(LUMIRAY) | recruiting | Phase 1 | 45 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07224503 | C-SMART vs BE Well for Patients With Brain Tumors | recruiting | N/A | 56 | Virginia Commonwealth UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer(KLK2-PASenger) | recruiting | Phase 3 | 800 | Janssen Research & Development, LLCINDUSTRY | 17 | Sep 25, 2026 | clinicaltrials |
| NCT07227025 | A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer(KaRAnaSa) | recruiting | Phase 1 / Phase 2 | 60 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
Data updated 3 days agoSource updated unknownsource: clinicaltrials